Literature DB >> 17277099

Unique human tumor antigens: immunobiology and use in clinical trials.

Giorgio Parmiani1, Annamaria De Filippo, Luisa Novellino, Chiara Castelli.   

Abstract

The individual, unique tumor Ags, which characterize each single tumor, were described 50 years ago in rodents but their molecular characterization was limited to few of them and obtained during the last 20 years. Here we summarize the evidence for the existence and the biological role of such Ags in human tumors, although such evidence was provided only during the last 10 years and by a limited number of studies, a fact leading to a misrepresentation of unique Ags in human tumor immunology. This was also due to the increasing knowledge on the shared, self-human tumor Ags, which have been extensively used as cancer vaccines. In this review, we highlight the biological and clinical importance of unique Ags and suggest how they could be used in clinical studies aimed at assessing their immunogenic and clinical potential both in active and adoptive immunotherapy of human tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277099     DOI: 10.4049/jimmunol.178.4.1975

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

Review 1.  Macrophages as mediators of tumor immunosurveillance.

Authors:  Siddhartha Jaiswal; Mark P Chao; Ravindra Majeti; Irving L Weissman
Journal:  Trends Immunol       Date:  2010-05-07       Impact factor: 16.687

2.  In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer.

Authors:  Hyun Ju Lee; Cheol Yi Hong; Mi Hyun Kim; Youn Kyung Lee; Thanh Nhan Nguyen-Pham; Byoung Chul Park; Deok Hwan Yang; Ik Joo Chung; Hyeoung Joon Kim; Je Jung Lee
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

3.  Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.

Authors:  Maria Aurora Grimaudo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.

Authors:  Malgorzata Czystowska; Miroslaw J Szczepanski; Marta Szajnik; Karen Quadrini; Harvey Brandwein; John W Hadden; Theresa L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2010-12-23       Impact factor: 6.968

5.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers.

Authors:  Michal Bassani-Sternberg; Eilon Barnea; Ilan Beer; Irit Avivi; Tami Katz; Arie Admon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

Review 6.  Adoptive immunotherapy: good habits instilled at youth have long-term benefits.

Authors:  Chrystal M Paulos; Megan M Suhoski; Gabriela Plesa; Tianying Jiang; Samik Basu; Tatiana N Golovina; Shuguang Jiang; Nicole A Aqui; Daniel J Powell; Bruce L Levine; Richard G Carroll; James L Riley; Carl H June
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 7.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

8.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

Review 9.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.

Authors:  Stéphane Champiat; Keith E Garrison; Rui André Saraiva Raposo; Benjamin J Burwitz; Jason Reed; Ravi Tandon; Vanessa A York; Laura P Newman; Francesca A Nimityongskul; Nancy A Wilson; Rafael R Almeida; Jeffrey N Martin; Steven G Deeks; Michael G Rosenberg; Andrew A Wiznia; Gerald E Spotts; Christopher D Pilcher; Fredrick M Hecht; Mario A Ostrowski; Jonah B Sacha; Douglas F Nixon
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.